The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

>850,000

Individuals in the CENTOGENE Biodatabank

>400,000

Collected biosamples

30,000

Active physicians in our network

>19,000

Genes covered in testing portfolio

Working together with our patients, physicians, and partners to diagnose, understand, and treat rare, metabolic, and neurodegenerative diseases.

About our company

Diagnostics

Now Available: MOx 2.0 With Transcriptomics!

Revolutionize precision medicine with RNA sequencing for your rare and neurodegenerative disease patients.

Explore more

Pharma

CENTOGENE Registries

Accelerate and de-risk resource-intensive drug discovery, development, and commercialization processes with unique Real-World Evidence (RWE) on rare and neurodegenerative disease patient cohorts

Find out more

Diagnose.

CENTOGENE Baby Hand image reference nathan-dumlao-EytWx3BOrwI-unsplash

Diagnose.

To create a map, we integrate omic data from patients with the same disease to form an atlas representing a comprehensive collection of unique and detailed clinical and biochemical information about each rare disease.

Learn more

Understand.

CENTOGENE Why Choose Header Helix DNA

Understand.

Understanding the details of disease pathways – faulty genes and how they affect associated proteins, and how that leads to specific symptoms – can provide our pharmaceutical partners with valuable clues on how best to research treatments, by developing a drug to target specific molecules along disease pathways for example.

Learn more

Treat.

CENTOGENE Operationalising Clinical Trials Laboratory Scene

Treat.

The combination of omic technologies can identify drugs and drug targets with greater certainty, reducing the risk of failure and making drug development for rare diseases more financially attractive to pharma. Our goal: to enable the cure of 100 diseases in 10 years.

Learn more

Top Company News

CENTOGENE Receives Delisting Notice From Nasdaq

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a…

Read more

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data…

Read more

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

TUCSON, Ariz., CAMBRIDGE, Mass., and ROSTOCK, Germany and BERLIN, June 20, 2024 – Critical Path Institute (C-Path), a leader in forming collaborations…

Read more

Visit Our Online Ordering Portal

CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.

Order a Test

CENTOGENE CentoPortal Logo